Profile data is unavailable for this security.
About the company
Albert David Limited is an India-based pharmaceutical company. The Company's principal business is manufacturing and trading of pharmaceutical formulations, infusion solutions, herbal dosage forms and bulk drugs by way of domestic sale or export. Its product categories include formulations and bulk drugs. Its product range includes Placentrex range, Anaflam range and BREAZE range. Its formulations include parenteral, oral/enteral, topical agents and vision care. Its parenteral categories include amino acids infusion, anti-microbial, anti-leishmaniasis (kalazar), haemostat (inj), lvp, neurotropic vitamin and placenta extract. The Company's oral/enteral categories include amino acids oral, anthelmintic, anti-microbial, anti-ulcer ants, anti-vertigo, appetite stimulants, anti-tubercular, expectorant / cough syrup, hematinic, haemostat, hepato protective (ayurveda) and hepato protective (others). Its vision care categories include anti glaucoma, anti-infective and NSAID.
- Revenue in INR (TTM)3.65bn
- Net income in INR685.47m
- Incorporated1938
- Employees1.50k
- LocationAlbert David Ltd15, Chittaranjan Avenue, 2nd FloorKOLKATA 700001IndiaIND
- Phone+91 3 322302330
- Fax+91 3 322628439
- Websitehttps://www.albertdavidindia.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kilitch Drugs (India) Ltd | 1.58bn | 164.61m | 5.04bn | 168.00 | 30.51 | 2.66 | 29.07 | 3.20 | 10.28 | 10.28 | 98.44 | 117.72 | 0.6347 | 26.77 | 2.29 | 9,377,369.00 | 5.70 | 3.38 | 7.93 | 4.76 | 34.75 | 35.33 | 8.98 | 6.17 | 2.01 | 2.81 | 0.1467 | 0.00 | 10.58 | 13.35 | 39.75 | 30.69 | -19.45 | -- |
| ZIM Laboratories Ltd | 3.88bn | 161.50m | 5.08bn | 556.00 | 31.48 | 2.09 | 14.96 | 1.31 | 3.31 | 3.31 | 79.19 | 49.82 | 0.9788 | 2.67 | 5.18 | 6,980,632.00 | 4.07 | 3.88 | 5.70 | 6.54 | 53.95 | 47.45 | 4.16 | 3.97 | 0.9475 | 2.77 | 0.3004 | 1.21 | -7.80 | 1.84 | -29.42 | 2.37 | 29.41 | -- |
| Lyka Labs Ltd | 1.32bn | 33.80m | 5.11bn | 423.00 | 155.33 | 5.17 | 41.29 | 3.89 | 0.9226 | 0.9226 | 37.94 | 27.71 | 0.8222 | 6.01 | 3.92 | 3,111,116.00 | 1.95 | -5.48 | 2.50 | -8.30 | 59.65 | 60.82 | 2.38 | -9.16 | 1.23 | 2.34 | 0.2627 | -- | 19.47 | 9.45 | 81.16 | -- | 13.88 | -- |
| Accent Microcell Ltd | 2.62bn | 325.33m | 5.19bn | 174.00 | 12.46 | 2.91 | 14.48 | 1.98 | 19.80 | 19.80 | 141.04 | 84.68 | 1.65 | 4.64 | 6.67 | 15,070,950.00 | 20.43 | -- | 24.77 | -- | 32.30 | -- | 12.41 | -- | 4.81 | -- | 0.0114 | -- | 24.45 | -- | 146.63 | -- | -- | -- |
| Medicamen Biotech Ltd | 1.82bn | 64.80m | 5.73bn | 378.00 | 63.48 | 2.64 | 41.51 | 3.15 | 7.10 | 7.10 | 165.42 | 170.67 | 0.6199 | 1.67 | 2.76 | 4,804,595.00 | 1.99 | 5.89 | 2.76 | 8.45 | 46.53 | 36.54 | 3.22 | 9.58 | 1.41 | 2.67 | 0.0854 | 8.46 | 27.29 | 7.90 | -26.36 | -1.89 | -16.71 | 0.00 |
| IND Swift Laboratories Ltd | 7.26bn | 3.73bn | 6.15bn | 47.00 | 1.64 | 0.6075 | 1.54 | 0.8465 | 63.24 | 63.24 | 123.25 | 171.20 | 0.486 | 1.73 | 2.54 | 154,462,200.00 | 25.01 | 5.00 | 29.88 | 6.13 | 46.23 | 41.12 | 51.47 | 8.52 | 3.51 | 7.87 | 0.016 | 0.00 | 6.10 | 11.10 | 784.44 | 70.82 | 23.60 | -- |
| Sakar Healthcare Ltd | 1.64bn | 124.03m | 6.39bn | 325.00 | 51.74 | 2.08 | 20.05 | 3.89 | 5.68 | 5.68 | 75.48 | 141.51 | 0.4312 | 3.22 | 7.45 | 5,052,619.00 | 3.25 | 5.26 | 3.85 | 6.28 | 44.83 | 43.47 | 7.55 | 10.12 | 0.6515 | 3.28 | 0.2374 | -- | 14.99 | 17.58 | -8.53 | 11.76 | 19.05 | -- |
| Albert David Ltd | 3.65bn | 685.47m | 7.33bn | 1.50k | 10.70 | 1.77 | 9.71 | 2.01 | 120.12 | 120.12 | 639.84 | 724.06 | 0.7377 | 2.83 | 10.89 | 2,439,081.00 | 13.85 | 10.00 | 17.15 | 13.15 | 66.12 | 59.85 | 18.77 | 11.87 | 3.65 | 53.46 | 0.0085 | 12.89 | 6.12 | 2.72 | 108.49 | 33.59 | 40.87 | 13.90 |
| Wanbury Ltd | 5.77bn | 529.62m | 7.36bn | 1.49k | 14.27 | 18.99 | 11.12 | 1.27 | 15.73 | 15.73 | 173.33 | 11.83 | 1.55 | 7.95 | 6.17 | 3,871,231.00 | 14.26 | 11.63 | 39.18 | -- | 49.84 | 42.46 | 9.18 | 7.62 | 0.6908 | 1.71 | 0.8235 | -- | 15.21 | 8.02 | 638.26 | -- | 29.87 | -- |
| Nectar Lifesciences Ltd | 16.79bn | 107.27m | 7.84bn | 1.69k | 73.39 | 0.7278 | 10.92 | 0.4671 | 0.4766 | 0.4766 | 73.70 | 48.06 | 0.7764 | 1.67 | 4.94 | 9,960,952.00 | 0.496 | -0.2956 | 0.8778 | -0.541 | 30.41 | 16.49 | 0.6388 | -0.4053 | 0.5576 | 1.25 | 0.3686 | -- | 10.53 | -9.56 | 120.66 | -36.29 | -5.06 | -- |
| Holder | Shares | % Held |
|---|---|---|
| General Insurance Corp. of India (Invt Port)as of 31 Dec 2023 | 93.92k | 1.65% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 578.00 | 0.01% |
